MINT
Recruiting
99 years and younger
All
Phase
N/A
10 participants needed
1 Location
Brief description of study
To assess the effect of nintedanib on preserving L-PF measured symptom levels (cough, dyspnea, energy), impacts of disease, and quality of life in patients with MA-ILD who are also receiving SOC treatment.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 855404
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting